Our iPSC banks utilize specialized reprogramming technology to transform commercial-use donor consented, clinically approved, cord blood collections into HLA-homozygous lines that are immune compatible with a wide population. The cell banks meet major regulatory agency requirements and the iPSC lines and corresponding donor tissue undergo extensive characterization.

Download the Document

* denotes a required field

Please fill out the information below. If you are already registered, login and this information will be filled out for you.

Name *
Please enter your first and last name.
Company/Institution *
Please enter the name of the company or institution you work at.
Address *
Please enter your mailing address.
Email Address *
Please enter the e-mail address you would like to be contacted at.
Work Phone Number *
Please enter the phone number you would like to be contacted at.

By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.

Industrializing iPSC-Based Cell Therapies

Oops! It looks like there were some errors.

Download the Document